Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of GRT6019 in Healthy Male Participants
NCT07347548Phase 1Completed
- Sponsor
- Grünenthal GmbH
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tegacorat in Duchenne muscular dystrophy (DMD) (3 cohorts), sponsored by Grünenthal GmbH. Primary endpoints: Number of participants with Adverse Events at 4 weeks, Number of participants with Serious Adverse Events at 4 weeks and 2 more. Started Jan 2026; status: completed.
02
Drugs
tegacorat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07347548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347548.